OrthoTrophix, Inc.
- Biotech or pharma, therapeutic R&D
OrthoTrophix has started the U.S. registration study of TPX-100, a candidate for the first-in-class disease modifying osteoarthritis drug (DMOAD). TPX-100 has demonstrated statistically significant clinical and structural improvements as compared to placebo in mild to severe knee osteoarthritis (OA) patients in the preceding Phase 2 studies. OrthoTrophix is open to partnering outside the U.S.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}